Praxis Partners in Recruitment for Serious Heart Condition
Brentwood, Tenn. - April 9, 2009 - Praxis, a company specializing in centralized patient recruitment for clinical research studies, will partner with a successful Biotech company to provide strategic patient recruitment services for a nation wide study involving a serious heart condition.
This trial seeks to test study drug effectiveness in patients with heart failure. “There are several key strategic measures that need to be taken in a study of this nature. Recognizing that the older patient population will, in most cases, be supported by some family member(s) it will be key that our strategic messaging talk to both parties simultaneously to help keep budgets under control for the sponsor.” Donna Beasley, VP of Operations with Praxis also adds, “There are roughly 3.5 million people in the U.S. that suffer from this serious condition. A major point of significance here is when you look outside the U.S. For example, in Europe there are approximately 14 million that suffer from heart failure. This drug stands to bring benefit to this patient population all over the world.”
Praxis will be providing strategy on all fronts including protocol & study feasibility as well as site selection guidance and positioning. Praxis will also be providing full service recruitment services including all the necessary informational tools and devices as well as direct to consumer tactics and the appropriate digital options.
Praxis Communications, Inc., headquartered in Brentwood, Tenn., provides the pharmaceutical and biotech industries with a wide range of global services for patient recruitment and retention for clinical trials including patient profiling, recruitment planning, centralized fulfillment, media relations, advertising, and program management. For more information, call Praxis at (615) 312-8207 or visit
www.GoPraxis.com
.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
